ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Pharma Trend Honors the Best Pharmaceutical Companies and the Most Innovative Products 2022

By: Magic PR

For the second consecutive year, the “Most Innovative Product®” award goes to the BioNTech/Pfizer Covid-19 vaccine Comirnaty®. The biotechnology company was further delighted to receive the award “The Golden Tablet®”. Janssen-Cilag is voted the best pharmaceutical company in Germany in the 2022 Pharma Trend Ranking. Novartis Pharma and Bayer Vital come in at number 2 and 3, followed by Sanofi at number 4 and Pfizer at number 5. A total of 16 products in 7 categories received the “Most Innovative Product®” award.

(Munich, October 10, 2022) The ranking “Best pharmaceutical companies in Germany 2022” is set. Janssen-Cilag, Novartis Pharma, Bayer Vital, Sanofi and Pfizer occupy spots one to five in the Pharma Trend Image & Innovation Award survey. It is carried out annually by the market research company Harris Interactive on behalf of the Starnberg-based Eurecon Verlag, surveying 700 doctors, 100 pharmacists and 600 patients from Germany. In addition, the four winners for the “The Golden Tablet®” award were announced: BioNTech, InfectoPharm, Jenapharm and Janssen-Cilag.

Sixteen other winners were delighted to receive the “Most Innovative Product®” award. Among this year’s award winners in the Rx (prescription drugs) category are Comirnaty® (Covid-19 vaccination) by BioNTech, Paxlovid® (Covid-19 treatment) by Pfizer, Palforzia® (peanut allergy) by Aimmune Therapeutics, Cariban® (pregnancy sickness) by ITF Pharma, Slinda® (oral contraception) and DeflaGyn® (cervical dysplasia) by Exeltis, Nubeqa® (prostate cancer) by Bayer Vital, Klisyri® (actinic keratosis) by Almirall, Ryeqo® (uterine fibroids) by Gedeon Richter. BioMarin’s Voxzogo® (achondroplasia) won in the category Orphan Drugs (treatment of rare diseases) and Daiichi Sankyo’s Enhertu® (breast cancer) in the category Specialty Care.

In the OTC (over-the-counter medicines) category, the pharmacists awarded Algovir® (cold) by Hermes Arzneimittel and Oyono® (difficulties falling asleep) by Divapharma. The award in the Diagnostics category went to Dermanostic (online dermatology practice) and in the Digital Health Application category to the MyIUS app (intrauterine system support) by Jenapharm. In the category Leap Innovations – Nucleic Acid-Based Drug Development, Cardior Pharmaceuticals ranked 1st, followed by rnatics and Pantherna Therapeutics at 2nd and 3rd.

The publication of the ranking and the presentation of the subject-specific awards took place on September 13, 2022 in the auditorium of the Deutsches Museum in Munich. It was part of the 23rd Pharma Trend Image & Innovation Award – again this year under the patronage of the Bavarian Minister of Health Klaus Holetschek. The basis for the ranking and the awards is the Pharma Trend market research, which has been collected in the Rx category in Germany since 2000. Since 2018, the categories OTC and Orphan Drugs are included and since 2019 the category Specialty Care. In 2021, the categories Diagnostics and Digital Health Application were added. The survey is carried out with 1,400 doctors, pharmacists and patients.

Further information on the ranking and the awards at https://pharma-trend.com/en/pharma-award/

Source: https://thenewsfront.com/pharma-trend-honors-the-best-pharmaceutical-companies-and-the-most-innovative-products-2022/

About Pharma Trend

Contact Pharma Trend




Website: https://pharma-trend.com/


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.